Methods and compositions for preventing skin toxicities caused by biological targeted cancer drugs
AssigneesHadasit Medical Research Services and Development Ltd., Yissum Research Development Company of the Hebrew University of Jersusalem Ltd.
InventorsOfra Benny, Sharon Merims, Yelena Mostinski
Life of this patent
Estimating the term…
Abstract
Provided are methods for inhibiting binding of systemically administered drugs to a target in the skin by topically administering materials prior to or concomitantly with administration of the systemic drugs.
Claims4
A method for interrupting binding of cetuximab to epidermal growth factor receptor (EGFR) in a skin region, the method comprising administering to the skin region at least one material prior to, concomitantly with or following systemic administration of the cetuximab, to thereby interrupt binding of the systemically administered cetuximab to EGFR in the skin region, wherein the at least one material is:
Dependencies are inferred from the claim text.